Ordering
Available Variants5 mg
CHA.31138-5mg
Price
€172.80
Available – Dispatch in 14 days
25 mg
CHA.31138-25mg
Price
€552.80
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.31138-5mg | €172.80 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.31138-25mg | €552.80 |
≥98% (HPLC), powder, glucose homeostasis regulator
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C13H15Cl2N3O2S |
|---|---|
| CAS Number | 281209-71-0 |
| Molecular Weight | 348.25 |
| MDL number | MFCD11521508 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
| Storage condition | desiccated |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
The GLP-1R agonist, with a CAS number of 281209-71-0, is a synthetic peptide that mimics the action of the naturally occurring incretin hormone glucagon-like peptide-1. This compound has been shown to exhibit a high degree of specificity and potency for the GLP-1 receptor, leading to increased glucose-dependent insulin secretion and decreased glucagon secretion. As a result, GLP-1R agonists have been found to be effective in the treatment of type 2 diabetes, with benefits including improved glycemic control and reduced risk of major adverse cardiovascular events. The pharmacokinetic profile of this compound is characterized by a prolonged duration of action, allowing for once-daily or once-weekly dosing regimens. Overall, the GLP-1R agonist represents a valuable therapeutic option for the management of type 2 diabetes and related metabolic disorders. Its mechanism of action and clinical efficacy have been extensively studied.
